Synthesis 2024; 56(09): 1460-1464
DOI: 10.1055/a-2236-0413
paper

An Improved and Scalable Synthesis of the Potent SREBP Inhibitor KK-052 via [3+2] Cycloaddition

Fumihiro Kawagoe
a   Faculty of Pharmaceutical Sciences, Teikyo University, 2-11-1 Kaga, Itabashi, Tokyo 173-8605, Japan
,
Sayuri Mototani
a   Faculty of Pharmaceutical Sciences, Teikyo University, 2-11-1 Kaga, Itabashi, Tokyo 173-8605, Japan
,
Yasushi Takemoto
b   Institute for Chemical Research and Institute for Integrated Cell-Material Sciences (WPI-iCeMS), Kyoto University, Uji, Kyoto 611-0011, Japan
,
Motonari Uesugi
b   Institute for Chemical Research and Institute for Integrated Cell-Material Sciences (WPI-iCeMS), Kyoto University, Uji, Kyoto 611-0011, Japan
c   School of Pharmacy, Fudan University, Shanghai 201203, P. R. of China
,
Atsushi Kittaka
a   Faculty of Pharmaceutical Sciences, Teikyo University, 2-11-1 Kaga, Itabashi, Tokyo 173-8605, Japan
› Institutsangaben
This work was supported in part by Grants-in-Aid from the Japan Society for the Promotion of Science (No. 22K14688 to F.K. and No. 23K06029 to A.K.).


Abstract

KK-052 is a novel vitamin-D-based selective sterol regulatory element-binding protein (SREBP) suppressor that lacks vitamin D genomic activity mediated through the vitamin D receptor in both in vitro and in vivo settings. In our initial synthetic effort, KK-052 was produced as one of the structural isomers obtained via the Mitsunobu reaction involving a CD-ring allyl alcohol and 5-phenyl-1H-tetrazole. In this work, we present a refined methodology for enhancing the selective synthesis of KK-052 through a [3+2] cycloaddition between a CD-ring benzimidoyl chloride and sodium azide, a technique that proved amenable to gram-scale production. Additionally, this synthetic method permitted the production of a more potent m-methyl analogue of KK-052.

Supporting Information



Publikationsverlauf

Eingereicht: 04. Dezember 2023

Angenommen nach Revision: 28. Dezember 2023

Accepted Manuscript online:
28. Dezember 2023

Artikel online veröffentlicht:
07. Februar 2024

© 2023. Thieme. All rights reserved

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 
  • References

  • 1 Present address: Department of Radiation Oncology, Fukushima Medical University School of Medicine, Hikarigaoka 1, Fukushima, Fukushima 960-1295, Japan.
  • 2 Kawagoe F, Mendoza A, Hayata Y, Asano L, Kotake K, Mototani S, Kawamura S, Kurosaki S, Akagi Y, Takemoto Y, Nagasawa K, Nakagawa H, Uesugi M, Kittaka A. J. Med. Chem. 2021; 64: 5689
  • 3 Asano L, Watanabe M, Ryoden Y, Usuda K, Yamaguchi T, Khambu B, Takashima M, Sato S, Sakai J, Nagasawa K, Uesugi M. Cell Chem. Biol. 2017; 24: 207
  • 4 Kawagoe F, Mototani S, Mendoza A, Takemoto Y, Uesugi M, Kittaka A. RSC Med. Chem. 2023; 14: 2030
  • 5 Shimano H, Sato R. Nature Rev. Endocrinol. 2017; 13: 710
  • 6 Jin X, Demere Z, Nair K, Ali A, Ferraro GB, Natoli T, Deik A, Petronio L, Tang AA, Zhu C, Wang L, Rosenberg D, Mangena V, Roth J, Chung K, Jain RK, Clish CB, Vander Heiden MG, Golub TR. Nature 2020; 588: 331
  • 7 Li Y, Wu S, Zhao X, Hao S, Li F, Wang Y, Liu B, Zhang D, Wang Y, Zhou H. Front. Pharmacol. 2023; 14: 1130747
  • 8 Zhao Q, Lin X, Wang G. Front. Oncol. 2022; 12: 952371
  • 9 Wen Y.-A, Xiong X, Zaytseva YY, Napier DL, Vallee E, Li AT, Wang C, Weiss HL, Evers BM, Gao T. Cell Death Dis. 2018; 9: 265
  • 10 Dorotea D, Koya D, Ha H. Front. Pharmacol. 2020; 11: 265
  • 11 Ono K, Yoshida A, Saito N, Fujishima T, Honzawa S, Suhara Y, Kishimoto S, Sugiura T, Waku K, Takayama H, Kittaka A. J. Org. Chem. 2003; 68: 7407
  • 12 Katritzky AR, Cai C, Meher NK. Synthesis 2007; 1204
  • 13 Kabada PK. J. Org. Chem. 1976; 41: 1073
  • 14 Kawagoe F, Mototani S, Yasuda K, Nagasawa K, Uesugi M, Sakaki T, Kittaka A. J. Steroid Biochem. Mol. Biol. 2019; 195: 105477